CVI42 vs EchoNext
AI Verdict
Choose CVI42 if…
Choose CVI42 if your institution requires a comprehensive, AI-enabled platform for advanced cardiac and vascular imaging analysis using both CT and MRI. It is ideal for cardiologists and radiologists who need detailed plaque analysis, advanced CMR automation (like T1 mapping and 4D flow pre-processing), and vascular CT analysis for diagnosis, planning, and post-treatment surveillance, all within a unified workflow. This tool is particularly well-suited for centers aiming to integrate anatomy, function, and inflammation assessment for a holistic view of patient health.
View CVI42 →Choose EchoNext if…
Choose EchoNext if your primary need is an accessible, non-invasive AI tool for early detection and screening of hidden structural heart disease from standard 12-lead ECGs. This is particularly beneficial for broad access screening in various clinical settings, from major hospitals to community practices, to identify patients at risk for conditions like heart failure, valve disease, and pulmonary hypertension who may require further echocardiographic evaluation. It is designed to bridge the gap in early structural heart disease detection, especially where echocardiography access might be limited.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CVI42CVI42 emphasizes an intuitive user experience with streamlined workflows for both CT and CMR studies, aiming to reduce reporting times and clerical workload. EchoNext, while integrated into the OpenEvidence platform, focuses more on its diagnostic capabilities rather than specific user interface benefits. CVI42 also offers multi-language support and flexible deployment options (standalone or client/server), further enhancing its usability in diverse clinical settings.
Clinical Value
EchoNextEchoNext has demonstrated superior clinical value by accurately identifying structural heart disease from ECGs, outperforming cardiologists in studies. It has received FDA clearance for six indications, including heart failure, valve disease, and pulmonary hypertension, and has been credited with detecting undiagnosed heart failure that led to a heart transplant. CVI42 offers comprehensive cardiac and vascular imaging analysis with AI-automated segmentation and plaque analysis, which is valuable for diagnosis and planning, but EchoNext's ability to detect hidden structural heart disease from a routine, inexpensive test like an ECG represents a significant advancement in early detection and patient care.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, with discounts for annual commitments and clear details on implementation fees. CVI42 requires contacting for pricing, with estimates ranging from $5,000 for a single user perpetual license to over $250,000 for a large enterprise, plus variable implementation and maintenance costs. EchoNext's clear pricing structure and lower entry point likely offer better value for a broader range of practices, especially smaller ones or those looking for a more predictable cost model.
Enterprise Readiness
CVI42CVI42 is designed for enterprise environments, supporting both standalone and client/server deployments with full DICOM connectivity to PACS and HL7 compatibility. It also offers advanced enterprise security features like Single Sign-on (SSO) and Multi-factor Authentication (MFA). EchoNext is available through the OpenEvidence platform and is designed for broad access, but CVI42's detailed specifications for network deployment, data security (local processing), and integration capabilities suggest a more robust enterprise-grade solution.
Innovation
EchoNextEchoNext represents a significant innovation as the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a widely available and inexpensive test. This capability addresses a critical gap in early detection for cardiovascular disease. While CVI42 offers advanced AI for cardiac imaging analysis and continuous improvements, EchoNext's novel approach to leveraging ECG data for broad-scale screening is a more groundbreaking innovation in the field.
Support & Docs
CVI42CVI42 explicitly states it offers world-class support and clinical teams, global support in multiple languages and time zones, and provides extensive documentation and archived tutorials. EchoNext's documentation and support details are not as extensively highlighted in the provided information, making CVI42 the stronger contender in this dimension due to its explicit commitment to comprehensive support and resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CVI42 | EchoNext |
|---|---|---|
| Name | CVI42 | EchoNext |
| Company | CIRCLE CARDIOVASCULAR IMAGING | Pathway Labs |
| Description | CVI42 is an AI-enabled software platform by Circle Cardiovascular Imaging for comprehensive cardiac and vascular imaging analysis, enhancing diagnosis, planning, and patient care with advanced CT and MRI tools. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AI-automated coronary lumen and wall segmentation, Comprehensive coronary plaque analysis (calcified, non-calcified, low-attenuation), Advanced CMR automation (T1 mapping, 4D flow pre-processing), Vascular CT analysis and planning tools, Automated detection of suspected coronary lesions, Pericoronary Adipose Tissue (PCAT) analysis (research use only), 3D visualization and image fusion, Automated contouring of regions of interest | AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support |
Videos
Demos, reviews, and walkthroughs featuring CVI42 and EchoNext.